From The Stage

Mark Bethers

Posted by Carla / /

As Vice President of Global Human Resources & Facilities, Mark is involved in shaping the company’s overall corporate talent strategy, working closely with the entire leadership team to ensure human resources needs are met across the organization. Mark brings more than 20 years of experience as a senior HR professional in biopharma manufacturing and professional services. Prior to joining BioAgilytix, Mark held global HR and operational leadership roles in a wide variety of organizations, including WasteZero, inVentiv Health, Pfizer, and Quintiles. His core strengths include recruiting top industry talent and…

Sean Blake

Posted by Krista Rossi / /

Sean Blake has more than 20 years of IT leadership experience in technology operations, project management, systems implementation, and application support, with extensive expertise in regulatory compliance including 21 CFR Part 11, Sarbanes-Oxley, FISMA, and FDA regulations. Having led complex projects across various companies in the pharmaceutical and biotechnology industries, Sean has proven his capabilities in executing critical IT strategies and guiding international, cross-functional, and multi-organizational teams. He is the former Director of Information Systems at BioCryst Pharmaceuticals, where he led the strategic planning, execution, and oversight of innovative policies…

Chad Briscoe, Ph.D.

Posted by Carla / /

As Chief Scientific Officer, Dr. Briscoe provides scientific and regulatory oversight to BioAgilytix’s global teams with strategic guidance in line with emerging scientific developments. A seasoned scientific executive, he brings nearly 25 years of experience leading operational and scientific innovation in the bioanalytical and biomarker segments of the pharmaceutical industry. Prior to joining BioAgilytix, he was executive director of global bioanalytical science for a large contract research organization, where he was responsible for global laboratory scientific strategy including team leadership and key client relationship oversight. Dr. Briscoe is a recognized…

Jim Datin

Posted by Sam Damico / /

Jim Datin is a seasoned executive with significant experience in the Pharmaceutical, Life Sciences and Biotech industries. Over the course of his 25+ year career, Jim has been a successful CEO, director, and executive in companies throughout the United States, Europe, and Asia.He is a proven leader and operator with deep experience leading emerging companies through periods of growth. Jim was previously EVP and Managing Director at Safeguard Scientifics, Inc. (NYSE:SFE) where he led the team that invested capital into Life Sciences and Healthcare related companies. He is a former…

Beth Heinz

Posted by Carla / /

Beth has more than 18 years of commercial experience with a background in strategic pharma as well as several years of in-laboratory experience. She also has technical expertise in genomics and proteomics applications. As Vice President of Business Development at BioAgilytix, Beth focuses on cultivating and managing both strong client relationships and strategic partnerships worldwide to ensure the company is able to continue to scale its growth in both USA and Europe. Since joining BioAgilytix in 2015, she has been instrumental in leading the business development team to achieve record…

Frank Horling, Ph.D.

Posted by Carla / /

Dr. Frank Horling brings nearly 20 years of scientific and leadership experience in the pharmaceutical and biotechnology industry, specializing in bioanalytical strategy and regulatory support up to market authorization with a strong focus in the area of immunogenicity. Just prior to joining BioAgilytix, Dr. Horling worked at IMC University of Applied Sciences Krems in Austria where he was Co-Head of the Research Institute for Applied Bioanalytics and Drug Development. Preceding that role he was the Associate Director of R&D at Shire and has also held senior scientific management positions at…

PD Dr. Arno Kromminga

Posted by Sam Damico / /

PD Dr. Arno Kromminga is a certified specialized immunologist with 20+ years expertise covering the entire cascade of assay strategy and characterization of immune responses against biological therapeutics. He co-founded IPM Biotech in 1996 for the research of chronic inflammatory diseases. Since then, he has led the company to become a pioneer in the area of immunogenicity, and brought the first biosimilar EPO to approval in Europe, as well as supported the first biosimilar EPO submission in the U.S. IPM Biotech was acquired by BioAgilytix in 2016, becoming BioAgilytix’s European…

Kathryn Lindley

Posted by Krista Rossi / /

Kathie has over 20 years of experience in academia and industry at UNC-Chapel Hill and GlaxoSmithKline. She has a wide range of experience in cell-based and immunoassay development by utilizing platforms, including ELISA, ELISpot, MSD, DELFIA, RIA, and FMAT. Kathie is also an expert in the use and interpretation of BIAcore technology due her extensive experience in developing high throughput primary antibody screens using the BIAcore A100. She has developed and holds patents on several monoclonal antibodies that are being progressed as therapeutic agents for sarcopenia, breast cancer, and osteoarthritis.…

Dominic Marasco, R.Ph.

Posted by Carla / /

Dominic “Nick” Marasco has more than 22 years of executive experience in C-suite strategy development, commercial operations, strategic business development, alliance management, and financial resourcing within the Pharmaceutical, Biotech and Medical Device industries. Just prior to joining BioAgilytix, he served as Executive Vice President, Global Business Development, Commercial at Syneos Health, where he led the overall strategic direction of the global business development team for the commercial division both in the U.S. and internationally. He was also previously Head of U.S. Sales for the Neuroscience Business Unit at Amgen, Inc.…

Jim McNally, Ph.D.

Posted by Krista Rossi / /

Dr. McNally has an extensive background in bioanalytical assay development and program leadership spanning nearly 20 years working in the pharmaceutical and biotechnology industry. Prior to joining BioAgilytix, Dr. McNally was Executive Director at CRISPR Therapeutics, where he lead a team of scientists to develop a portfolio of assays to support development of gene-based therapeutic candidates throughout their lifecycle. He has also previously held roles at Genzyme, Pfizer, EMD Serono, and Shire which have given him broad experience in the development of large molecule, gene therapy, and cell therapy biotherapeutics.…